Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10010882HBVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS30067833HIVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20012857HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20062294HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20023366HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20022730HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS20061784HPVENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS44016703HTLV-1ENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TVIS44049057HTLV-1ENSG00000105976.16protein_codingMETYesNo4233E6Y365
P08581
TCGA Plot Options
Drug Information
GeneMET
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0000915
UniProt IDP08581
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830